Marinus Pharmaceuticals Inc. (MRNS) Receives Buy Rating from Jefferies Group
Jefferies Group reiterated their buy rating on shares of Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) in a research report sent to investors on Monday. The brokerage currently has a $3.00 target price on the biopharmaceutical company’s stock.
A number of other equities analysts have also weighed in on the stock. Zacks Investment Research upgraded shares of Marinus Pharmaceuticals from a sell rating to a hold rating in a report on Friday, August 19th. Stifel Nicolaus reiterated a hold rating on shares of Marinus Pharmaceuticals in a report on Tuesday, June 28th. Goldman Sachs Group Inc. lowered shares of Marinus Pharmaceuticals from a buy rating to a neutral rating in a report on Tuesday, June 14th. Oppenheimer Holdings Inc. lowered shares of Marinus Pharmaceuticals from an outperform rating to a market perform rating in a report on Tuesday, June 14th. Finally, Royal Bank Of Canada lowered shares of Marinus Pharmaceuticals from an outperform rating to a sector perform rating and decreased their price target for the company from $14.00 to $2.00 in a report on Tuesday, June 14th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Marinus Pharmaceuticals currently has an average rating of Hold and a consensus target price of $7.90.
Marinus Pharmaceuticals (NASDAQ:MRNS) traded down 1.761% during trading on Monday, reaching $1.729. The company had a trading volume of 48,362 shares. The company’s market capitalization is $33.73 million. The stock has a 50 day moving average price of $1.73 and a 200-day moving average price of $3.26. Marinus Pharmaceuticals has a 52-week low of $1.19 and a 52-week high of $10.24.
Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by $0.08. On average, equities research analysts anticipate that Marinus Pharmaceuticals will post ($1.65) earnings per share for the current fiscal year.
In other Marinus Pharmaceuticals news, major shareholder Vii Lp Canaan sold 20,589 shares of the business’s stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $1.81, for a total value of $37,266.09. The sale was disclosed in a document filed with the SEC, which is available at this link. 5.00% of the stock is currently owned by company insiders.
An institutional investor recently raised its position in Marinus Pharmaceuticals stock. Vanguard Group Inc. boosted its position in Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) by 2.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 283,380 shares of the biopharmaceutical company’s stock after buying an additional 7,618 shares during the period. Vanguard Group Inc. owned about 1.45% of Marinus Pharmaceuticals worth $360,000 as of its most recent filing with the SEC. 45.64% of the stock is currently owned by institutional investors and hedge funds.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Stock Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.